Algorae Pharmaceuticals Names New Director, Details Indirect Equity Stakes

Living Cell Technologies ( (AU:1AI) ) has shared an update.

Algorae Pharmaceuticals has appointed David Gulland as a director effective 10 March 2026, and lodged an initial director’s interest notice stating he holds no shares or options in his own name. The filing discloses that his relevant interests arise indirectly through his spouse and a family-controlled entity, which together hold several million ordinary shares, unlisted options and performance rights in the company.

These indirect holdings include more than 4.9 million ordinary shares, unlisted options exercisable at $0.014 expiring in late 2029, and 42 million performance rights, signalling a significant economic exposure to Algorae despite the absence of direct personal holdings. The disclosure informs investors about potential alignment between the new director’s interests and shareholder value, and clarifies the structure of his economic stake for governance and compliance purposes.

The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.

More about Living Cell Technologies

Algorae Pharmaceuticals Limited is a pharmaceutical company, though the release provides no further detail on its specific therapeutic focus, products or market segments. The company is listed on the ASX and subject to Australian corporate and securities disclosure rules governing directors’ interests and shareholdings.

YTD Price Performance: 14.29%

Average Trading Volume: 1,464,938

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$27.41M

Learn more about 1AI stock on TipRanks’ Stock Analysis page.